ABT logo Abbott Laboratories +
Abbott Laboratories
+

Abbott Laboratories (ABT) Business News

Track Abbott Laboratories in real time with a live news feed covering Abbott Laboratories stock news, official press releases, company announcements, and an archive of historical Abbott Laboratories news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
4:26 AM | Friday | Aug 28, 2026 Defense World

AMG National Trust Bank Has $2.86 Million Holdings in Abbott Laboratories $ABT

NEW News Thumbnail
6:51 PM | Thursday | Aug 27, 2026 Zacks Investment Research

Abbott (ABT) Stock Sinks As Market Gains: Here's Why

News Thumbnail
3:15 PM | Thursday | Aug 27, 2026 24/7 Wall Street

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?

News Thumbnail
9:00 AM | Thursday | Aug 27, 2026 PRNewsWire

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

News Thumbnail
5:39 AM | Thursday | Aug 27, 2026 Defense World

Bank of New York Mellon Corp Reduces Stock Holdings in Abbott Laboratories $ABT

News Thumbnail
9:00 AM | Thursday | Aug 27, 2026 PRNewsWire

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

News Thumbnail
5:39 AM | Thursday | Aug 27, 2026 Defense World

Bank of New York Mellon Corp Reduces Stock Holdings in Abbott Laboratories $ABT

News Thumbnail
4:43 AM | Wednesday | Aug 26, 2026 Defense World

Abbott Laboratories $ABT Shares Acquired by Bank Hapoalim BM

News Thumbnail
11:26 AM | Tuesday | Aug 25, 2026 Zacks Investment Research

Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?

News Thumbnail
4:09 AM | Tuesday | Aug 25, 2026 Defense World

Gateway Wealth Partners LLC Sells 15,431 Shares of Abbott Laboratories $ABT

News Thumbnail
4:09 AM | Tuesday | Aug 25, 2026 Defense World

Choreo LLC Sells 4,580 Shares of Abbott Laboratories $ABT

News Thumbnail
4:09 AM | Tuesday | Aug 25, 2026 Defense World

Abbott Laboratories $ABT Shares Bought by Golden Reserve Retirement LLC

News Thumbnail
12:41 PM | Monday | Aug 24, 2026 Zacks Investment Research

NVST or ABT: Which Is the Better Value Stock Right Now?

News Thumbnail
11:21 AM | Monday | Aug 24, 2026 Zacks Investment Research

Here's What Is Shaping Abbott's Diagnostics Growth

News Thumbnail
10:15 AM | Monday | Aug 24, 2026 Fool - Investing News

Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead.

News Thumbnail

AMG National Trust Bank Has $2.86 Million Holdings in Abbott Laboratories $ABT

Defense World

4:26 AM | Friday | Aug 28, 2026

news photo
Loading...

AMG National Trust Bank decreased its stake in Abbott Laboratories (NYSE: ABT) by 30.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,489 shares of the healthcare product maker's stock after selling 13,890 shares during the period. AMG National

Read full article redirect
4:26 AM | Friday | Aug 28, 2026

AMG National Trust Bank Has $2.86 Million Holdings in Abbott Laboratories $ABT

Defense World

AMG National Trust Bank decreased its stake in Abbott Laboratories (NYSE: ABT) by 30.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,489 shares of the healthcare product maker's stock after selling 13,890 shares during the period. AMG National

Read full article arrow
NEW News Thumbnail
6:51 PM | Thursday | Aug 27, 2026

Abbott (ABT) Stock Sinks As Market Gains: Here's Why

Zacks Investment Research

Abbott (ABT) concluded the recent trading session at $111.59, signifying a -2.2% move from its prior day's close.

Read full article arrow
News Thumbnail
3:15 PM | Thursday | Aug 27, 2026

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?

24/7 Wall Street

Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.

Read full article arrow
News Thumbnail
9:00 AM | Thursday | Aug 27, 2026

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

PRNewsWire

Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication Amulet 360 builds upon Abbott's first-generation LAA device with design updates to enhance how the implant conforms to and seals the LAA to help reduce the risk of a stroke Recent clinical trial data show Amulet 360 met benchmarks for safety and effectiveness ABBOTT PARK, Ill., Aug. 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today it has received CE Mark for the Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce risk of stroke in patients with atrial fibrillation (AFib) not caused by a heart valve issue (non-valvular).

Read full article arrow
News Thumbnail
5:39 AM | Thursday | Aug 27, 2026

Bank of New York Mellon Corp Reduces Stock Holdings in Abbott Laboratories $ABT

Defense World

Bank of New York Mellon Corp lessened its stake in shares of Abbott Laboratories (NYSE: ABT) by 19.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,991,899 shares of the healthcare product maker's stock after selling 2,450,818 shares during the quarter.

Read full article arrow
News Thumbnail
9:00 AM | Thursday | Aug 27, 2026

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

PRNewsWire

Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication Amulet 360 builds upon Abbott's first-generation LAA device with design updates to enhance how the implant conforms to and seals the LAA to help reduce the risk of a stroke Recent clinical trial data show Amulet 360 met benchmarks for safety and effectiveness ABBOTT PARK, Ill., Aug. 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today it has received CE Mark for the Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce risk of stroke in patients with atrial fibrillation (AFib) not caused by a heart valve issue (non-valvular).

Read full article arrow
News Thumbnail
5:39 AM | Thursday | Aug 27, 2026

Bank of New York Mellon Corp Reduces Stock Holdings in Abbott Laboratories $ABT

Defense World

Bank of New York Mellon Corp lessened its stake in shares of Abbott Laboratories (NYSE: ABT) by 19.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,991,899 shares of the healthcare product maker's stock after selling 2,450,818 shares during the quarter.

Read full article arrow
News Thumbnail
4:43 AM | Wednesday | Aug 26, 2026

Abbott Laboratories $ABT Shares Acquired by Bank Hapoalim BM

Defense World

Bank Hapoalim BM boosted its holdings in Abbott Laboratories (NYSE: ABT) by 80.7% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,765 shares of the healthcare product maker's stock after purchasing an additional 5,699 shares during the

Read full article arrow
News Thumbnail
11:26 AM | Tuesday | Aug 25, 2026

Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?

Zacks Investment Research

ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.

Read full article arrow
News Thumbnail
4:09 AM | Tuesday | Aug 25, 2026

Gateway Wealth Partners LLC Sells 15,431 Shares of Abbott Laboratories $ABT

Defense World

Gateway Wealth Partners LLC lessened its stake in shares of Abbott Laboratories (NYSE: ABT) by 64.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,564 shares of the healthcare product maker's stock after selling 15,431 shares during the quarter. Gateway Wealth

Read full article arrow
News Thumbnail
4:09 AM | Tuesday | Aug 25, 2026

Choreo LLC Sells 4,580 Shares of Abbott Laboratories $ABT

Defense World

Choreo LLC cut its position in Abbott Laboratories (NYSE: ABT) by 4.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 100,143 shares of the healthcare product maker's stock after selling 4,580 shares during the quarter. Choreo LLC's holdings in Abbott Laboratories

Read full article arrow
News Thumbnail
4:09 AM | Tuesday | Aug 25, 2026

Abbott Laboratories $ABT Shares Bought by Golden Reserve Retirement LLC

Defense World

Golden Reserve Retirement LLC grew its holdings in Abbott Laboratories (NYSE: ABT) by 155.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,138 shares of the healthcare product maker's stock after acquiring an additional 5,557 shares during the quarter.

Read full article arrow
News Thumbnail
12:41 PM | Monday | Aug 24, 2026

NVST or ABT: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and Abbott (ABT). But which of these two stocks presents investors with the better value opportunity right now?

Read full article arrow
News Thumbnail
11:21 AM | Monday | Aug 24, 2026

Here's What Is Shaping Abbott's Diagnostics Growth

Zacks Investment Research

ABT's Diagnostics growth is being reshaped as weaker respiratory testing offsets healthy routine demand and 13% cancer diagnostics growth.

Read full article arrow
News Thumbnail
10:15 AM | Monday | Aug 24, 2026

Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead.

Fool - Investing News

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

Read full article arrow
News Thumbnail